> Forendo Pharma raised €4 million ($4.7 million) from Vesalius Biocapital III Partners. Statement
> Redx Pharma took a step toward restarting a phase 1/2a trial of its Porcupine inhibitor at a new starting dose. Release
> Arix Bioscience is looking for a new CEO. Joe Anderson, Ph.D., vacated the CEO chair by transitioning to the role of chief investment officer. Statement
> Kiadis Pharma enlarged a phase 3 trial of ATIR101. The addition of more participants pushed back the readout from the first half of 2019 to the second half of 2020. Release
> Adaptimmune raised $100 million in a registered direct offering. Statement